We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Frontier IP Group Plc | AQSE:FIPP.GB | Aquis Stock Exchange | Ordinary Share | GB00B63PS212 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.00 | -4.71% | 40.50 | 38.00 | 43.00 | 42.50 | 38.50 | 42.50 | 13,250 | 16:29:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMFIPP
Frontier IP Group plc
07 December 2016
RNS REACH
AIM: FIPP
7 December 2016
Frontier IP Group Plc
("Frontier IP" or the "Group")
New Portfolio Company - Tarsis Technology Limited
Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that it has received a 20 per cent. stake in Tarsis Technology Limited ("Tarsis"), the Group's third spin-out from the Department of Chemical Engineering and Biotechnology at the University of Cambridge.
Tarsis plans to develop and commercialise technology created by Dr. David Fairen-Jimenez, a Royal Society University Research Fellow at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, and his research team. The technology allows slower and more controlled delivery of drugs using metal-organic frameworks (MOFs). The pharmaceutical industry has demonstrated early interest in the technology.
Frontier IP's role will be to provide commercialisation services and in-depth pharmaceutical industry expertise. Dr. Campbell Wilson, a non-executive director of Frontier IP, has been appointed as a non-executive director of Tarsis. Dr. Wilson is currently a member (and past chairman) of the Board of the UK Pharmaceutical Licensing Group and has worked in the pharmaceutical industry for over 35 years.
Dr. Campbell Wilson, Non- Executive Director of Frontier IP and Director of Tarsis, said:
"We are looking forward to working with Dr. Fairen-Jimenez on this promising opportunity. Frontier IP brings experience in commercialising IP and relationships with key players in relevant markets. Dr. Fairen-Jimenez's technology approach combined with our support and network in the pharmaceutical space can help accelerate the commercialisation for this exciting technology."
Dr. David Fairen-Jimenez, Chief Executive of Tarsis, said:
"This is a great opportunity to see the state-of-the-art materials we prepare in our labs move into the market. The synergy between Frontier IP and their experience in new ventures and in the pharmaceutical industry combined with our leading work in advanced materials for drug delivery will give a strong commercial dimension to this project."
ENDS
Enquiries
Frontier IP Group Plc T: 0131 240 1251 Neil Crabb, Chief Executive Cantor Fitzgerald Europe T: 020 7894 7000 (Nominated Adviser and Joint Broker) David Foreman, Catherine Leftley, Corporate Finance David Banks, Sales Peterhouse Corporate Finance T: 020 7469 0935 Limited (Joint Broker) Lucy Williams Kreab T: 020 7074 1800 (Financial PR) Robert Speed, Matthew Jervois
Notes to Editor:
About Frontier IP Group plc
www.frontierip.co.uk.
Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABLBDDSUGBGLL
(END) Dow Jones Newswires
December 07, 2016 02:00 ET (07:00 GMT)
1 Year Frontier IP Chart |
1 Month Frontier IP Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions